🚀 VC round data is live in beta, check it out!
Scinopharm Taiwan Valuation Multiples
Discover revenue and EBITDA valuation multiples for Scinopharm Taiwan and similar public comparables like Maravai LifeSciences, Emergent BioSolutions, Aarti Pharmalabs, Dishman Carbogen Amics and more.
Scinopharm Taiwan Overview
About Scinopharm Taiwan
Scinopharm Taiwan Ltd is a specialty and generic drug manufacturing company. The company is engaged in the manufacturing of medicines, chemicals, biological technology services, active pharmaceutical ingredients, albumin medicines, injections, and new small molecule drugs. The company also conducts consulting and technical services. The Company's sales revenue mainly arises from the manufacture and sales of Active Pharmaceutical Ingredient and injection products.
Founded
1997
HQ
Employees
765
Website
Financials (FY)
EV
$477M
Scinopharm Taiwan Financials
Scinopharm Taiwan reported last fiscal year revenue of $101M and EBITDA of $21M.
In the same fiscal year, Scinopharm Taiwan generated $35M in gross profit, $21M in EBITDA, and $4M in net income.
Revenue (LTM)
Scinopharm Taiwan P&L
In the most recent fiscal year, Scinopharm Taiwan reported revenue of $101M and EBITDA of $21M.
Scinopharm Taiwan expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $101M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $35M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 35% | XXX | XXX | XXX |
| EBITDA | — | XXX | $21M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 3% | XXX | XXX | XXX |
| Net Profit | — | XXX | $4M | XXX | XXX | XXX |
| Net Margin | — | XXX | 4% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Scinopharm Taiwan Stock Performance
Scinopharm Taiwan has current market cap of $551M, and enterprise value of $477M.
Market Cap Evolution
Scinopharm Taiwan's stock price is $0.70.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $477M | $551M | 0.5% | XXX | XXX | XXX | $0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialScinopharm Taiwan Valuation Multiples
Scinopharm Taiwan trades at 4.7x EV/Revenue multiple, and 22.2x EV/EBITDA.
EV / Revenue (LTM)
Scinopharm Taiwan Financial Valuation Multiples
As of April 19, 2026, Scinopharm Taiwan has market cap of $551M and EV of $477M.
Equity research analysts estimate Scinopharm Taiwan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Scinopharm Taiwan has a P/E ratio of 126.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $551M | XXX | $551M | XXX | XXX | XXX |
| EV (current) | $477M | XXX | $477M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 22.2x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 137.5x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 13.7x | XXX | XXX | XXX |
| P/E | — | XXX | 126.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 50.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Scinopharm Taiwan Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Scinopharm Taiwan Margins & Growth Rates
Scinopharm Taiwan's revenue in the last fiscal year declined by (7%).
Scinopharm Taiwan's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Scinopharm Taiwan Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (7%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (26%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Scinopharm Taiwan Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Scinopharm Taiwan | XXX | XXX | XXX | XXX | XXX | XXX |
| Maravai LifeSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Emergent BioSolutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Aarti Pharmalabs | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Frontage Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Scinopharm Taiwan M&A Activity
Scinopharm Taiwan acquired XXX companies to date.
Last acquisition by Scinopharm Taiwan was on XXXXXXXX, XXXXX. Scinopharm Taiwan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Scinopharm Taiwan
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialScinopharm Taiwan Investment Activity
Scinopharm Taiwan invested in XXX companies to date.
Scinopharm Taiwan made its latest investment on XXXXXXXX, XXXXX. Scinopharm Taiwan invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Scinopharm Taiwan
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Scinopharm Taiwan
| When was Scinopharm Taiwan founded? | Scinopharm Taiwan was founded in 1997. |
| Where is Scinopharm Taiwan headquartered? | Scinopharm Taiwan is headquartered in Taiwan. |
| How many employees does Scinopharm Taiwan have? | As of today, Scinopharm Taiwan has over 765 employees. |
| Is Scinopharm Taiwan publicly listed? | Yes, Scinopharm Taiwan is a public company listed on Taiwan Stock Exchange. |
| What is the stock symbol of Scinopharm Taiwan? | Scinopharm Taiwan trades under 1789 ticker. |
| When did Scinopharm Taiwan go public? | Scinopharm Taiwan went public in 2011. |
| Who are competitors of Scinopharm Taiwan? | Scinopharm Taiwan main competitors are Maravai LifeSciences, Emergent BioSolutions, Aarti Pharmalabs, Dishman Carbogen Amics. |
| What is the current market cap of Scinopharm Taiwan? | Scinopharm Taiwan's current market cap is $551M. |
| What is the current revenue of Scinopharm Taiwan? | Scinopharm Taiwan's last fiscal year revenue is $101M. |
| What is the current EV/Revenue multiple of Scinopharm Taiwan? | Current revenue multiple of Scinopharm Taiwan is 4.7x. |
| Is Scinopharm Taiwan profitable? | No, Scinopharm Taiwan is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.